← Back to Search

Radiation Therapy

Treatment (SRS) for Brain metastases

N/A
Waitlist Available
Led By Samuel Chao, MD
Research Sponsored by Case Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This phase I/II trial studies the side effects and the best dose of stereotactic radiosurgery and to see how well it works in treating patients with large brain metastases. Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.

Eligible Conditions
  • Brain metastases
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Incidence of adverse events as assessed by CTCAE version 4.0 (Phase II)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (SRS)Experimental Treatment3 Interventions
Patients undergo SRS guided by CT and MRI.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
stereotactic radiosurgery
2011
Completed Phase 3
~1010
quality-of-life assessment
2012
Completed Phase 3
~2780
cognitive assessment
2005
Completed Phase 3
~1210

Find a Location

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor
467 Previous Clinical Trials
32,615 Total Patients Enrolled
Samuel Chao, MDPrincipal InvestigatorCleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
2 Previous Clinical Trials
170 Total Patients Enrolled
~1 spots leftby Mar 2025